Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ROCKWELL MEDICAL, INC. (RMTI)

Rockwell Medical agrees to buy Vantive hemodialysis business for $125 million

Mixed Impact 5 of 5 m&a Written later

On November 2, 2026, Rockwell Medical agreed to acquire Vantive's in-center hemodialysis business in 35 jurisdictions, with a $125 million base price financed mainly by seller loans and a convertible note from Vantive affiliates. The company also withdrew its previously issued 2026 guidance, citing expected transaction and financing expenses. Shareholders face substantially higher debt, potential dilution from the convertible note, and closing that is expected in mid-2027 and subject to regulatory approvals.

Key points

  • Equity and Asset Purchase Agreement with Vantive Limited dated November 2, 2026, covering the in-center hemodialysis business in 35 jurisdictions
  • Base purchase price of $125 million, funded by two $50 million term loans and a $25 million convertible note from Vantive affiliates, plus up to $45 million in earnout payments
  • 2026 guidance for net sales, gross margin, adjusted EBITDA and operating cash flow withdrawn
  • Expected closing in mid-2027, subject to regulatory approvals; combined business projected annual revenue of $400 million to $450 million

The filing

CompanyROCKWELL MEDICAL, INC. (RMTI)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:49 PM ET
Accession number0001104659-26-122103

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.